BioLife SolutionsBLFS +0.50%72 Cash Ratio is 4.44 as of Mar. 2026, which is 91% above its 10-year median of 2.33. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.72 (Fairly Valued). The stock has 4 warning signs investors should review. Among 843 Medical Devices & Instruments companies, BioLife Solutions ranks better than 85.17% on this metric.
BioLife Solutions has a Cash Ratio of 4.44. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for BioLife Solutions's Cash Ratio or its related term are showing as below:
BLFS'
s Cash Ratio Range Over the Past 10 Years
Min: 0.25 Med: 2.33 Max: 15.81
Current: 4.44
During the past 13 years, BioLife Solutions's highest Cash Ratio was 15.81. The lowest was 0.25. And the median was 2.33.
BLFS's Cash Ratio is ranked better than 85.17% of 843
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs BLFS: 4.44
BioLife Solutions (NAS:BLFS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BioLife Solutions Cash Ratio Related Terms
BioLife Solutions Cash Ratio Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions (BLFS) has a Cash Ratio of 4.44 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioLife Solutions and its competitors. This is 91% above median its historical median of 2.33. Over the past decade, BioLife Solutions' Cash Ratio has ranged from 0.25 to 15.81. According to the industry distribution chart, BioLife Solutions ranks #125 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 14.8%.
Is BioLife Solutions' Cash Ratio too high?
BioLife Solutions' current Cash Ratio of 4.44 is 91% above median its 10-year median of 2.33. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 15.81. The Medical Devices & Instruments industry median Cash Ratio is 0.97. BioLife Solutions' value of 4.44 is 357.7% above this industry median. Based on the distribution chart, BioLife Solutions ranks #125 out of 843 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Cash Ratio compare to STAA and ATRC?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #125 out of 843 companies for Cash Ratio. This places BioLife Solutions in the top 15% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.97. BioLife Solutions' value of 4.44 is 357.7% above this benchmark. Historically, BioLife Solutions' own Cash Ratio has ranged from 0.25 to 15.81 over the past decade. While the company's 10-year median is 2.33 vs. the industry median of 0.97, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Cash Ratio of 4.44 is 357.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Cash Ratio is 4.44, which is 91% above median its own 10-year median of 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.72, compared to a current price of $27.92 — trading 2.8% below its estimated fair value. The current Cash Ratio is 4.44, which is 91% above median its 10-year median of 2.33 and 357.7% above the Medical Devices & Instruments industry median of 0.97. BioLife Solutions' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Cash Ratio is 4.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be undervalued.
The current stock price of $27.92 is trading 2.8% below its estimated GF Value™ of $28.72.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Cash Ratio: 4.44 (91% above median its 10-year median of 2.33)
GF Value™: $28.72 vs. price of $27.92 (2.8% below fair value)
Industry Position: 357.7% above the Medical Devices & Instruments median (#125 of 843)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
